Filing Details

Accession Number:
0001209191-23-026681
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-02 18:14:21
Reporting Period:
2023-04-28
Accepted Time:
2023-05-02 18:14:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1598646 Minerva Neurosciences Inc. NERV Pharmaceutical Preparations (2834) 260784194
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610382 Geoff Race C/O Minerva Neurosciences, Inc.
1500 District Avenue
Burlington MA 01803
President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-28 46,987 $0.00 73,406 No 4 A Direct
Common Stock Disposition 2023-05-01 22,082 $3.85 51,324 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs"), representing 50% of the shares underlying the PRSUs. On April 28, 2023, the Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for roluperidone.
  2. The sales reported in this Form 4 represent nondiscretionary sales of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of the PRSUs.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.